|
1
|
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
|
J Clin Oncol
|
2003
|
3.88
|
|
2
|
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
|
J Clin Oncol
|
2011
|
1.99
|
|
3
|
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group.
|
J Clin Oncol
|
2008
|
1.46
|
|
4
|
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.
|
Support Care Cancer
|
2006
|
1.41
|
|
5
|
Cancer of the penis.
|
Crit Rev Oncol Hematol
|
2005
|
1.39
|
|
6
|
[Update on anticancer drugs].
|
Assist Inferm Ric
|
2014
|
1.38
|
|
7
|
Germ cell tumours of the testis.
|
Crit Rev Oncol Hematol
|
2005
|
1.37
|
|
8
|
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
|
Eur J Cancer
|
2005
|
1.36
|
|
9
|
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.
|
Health Qual Life Outcomes
|
2003
|
1.34
|
|
10
|
Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.
|
Support Care Cancer
|
2010
|
1.26
|
|
11
|
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
|
Clin Lung Cancer
|
2009
|
1.17
|
|
12
|
Renal cancer.
|
Crit Rev Oncol Hematol
|
2007
|
0.96
|
|
13
|
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
|
J Clin Oncol
|
2009
|
0.90
|
|
14
|
Acute emesis: moderately emetogenic chemotherapy.
|
Support Care Cancer
|
2004
|
0.90
|
|
15
|
Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey.
|
Support Care Cancer
|
2008
|
0.86
|
|
16
|
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
|
Support Care Cancer
|
2010
|
0.86
|
|
17
|
Acute emesis: moderately emetogenic chemotherapy.
|
Support Care Cancer
|
2010
|
0.83
|
|
18
|
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.
|
Support Care Cancer
|
2004
|
0.83
|
|
19
|
Evidence-based recommendations for the use of antiemetics in radiotherapy.
|
Radiother Oncol
|
2005
|
0.82
|
|
20
|
Treatment of lung cancer.
|
N Engl J Med
|
2009
|
0.82
|
|
21
|
Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis.
|
Crit Rev Oncol Hematol
|
2013
|
0.82
|
|
22
|
Is there still a role for the uniscale assessment of quality of life?
|
Tumori
|
2007
|
0.82
|
|
23
|
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study].
|
Recenti Prog Med
|
2007
|
0.81
|
|
24
|
The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants.
|
Support Care Cancer
|
2004
|
0.79
|
|
25
|
The cost of chemotherapy-induced nausea and vomiting in Italy.
|
Support Care Cancer
|
2006
|
0.77
|
|
26
|
Tackling off-label use of anticancer drugs.
|
J Clin Oncol
|
2012
|
0.75
|
|
27
|
Cetuximab for colorectal cancer.
|
N Engl J Med
|
2008
|
0.75
|
|
28
|
Cetuximab for metastatic colorectal cancer.
|
N Engl J Med
|
2009
|
0.75
|
|
29
|
Do we need new antiemetic guidelines?
|
Support Care Cancer
|
2002
|
0.75
|
|
30
|
Multinational Association of Supportive Cancer Care (MASCC).
|
Support Care Cancer
|
2003
|
0.75
|
|
31
|
Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials.
|
Tumori
|
2008
|
0.75
|
|
32
|
[Cancer-related fatigue].
|
Recenti Prog Med
|
2015
|
0.75
|
|
33
|
Antiemetic therapy.
|
Crit Rev Oncol Hematol
|
2002
|
0.75
|
|
34
|
[Methodology of drug utilization studies].
|
Suppl Tumori
|
2004
|
0.75
|
|
35
|
Surgical treatment of primitive thyroid lymphoma.
|
Tumori
|
2010
|
0.75
|